{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/68baea94f8dc6bde3858318e?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Developing New Therapies Through Partnership, Electricity, and Immunotherapy ","description":"<p>Novartis has agreed to license and develop Arrowhead Pharmaceuticals’ preclinical stage small interfering RNA (siRNA) therapy ARO-SNCA, a potential treatment for Parkinson’s disease and other synucleinopathies, plus additional targets. Two stories this week covered very different types of cell reprogramming techniques for therapy development. The first approach may overcome the time delays and safety risks of traditional immunotherapies, especially for patients with aggressive, late-stage disease. Meanwhile, electrical stimulation of macrophages could represent a new therapy to boost the body’s own repair processes in a range of injury and disease situations. Finally, Eli Lilly saw its shares&nbsp;climb&nbsp;5%&nbsp;this past week after announcing that its history-making oral obesity candidate, orforglipron, aced the Phase III ATTAIN-2 trial. </p><p><br></p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.</p><p><br></p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>:</p><p><br></p><p><a href=\"https://webinars.liebertpub.com/e/the-state-of-biotech-2025\" rel=\"noopener noreferrer\" target=\"_blank\">The State of Biotech Summit Registration</a></p><p><br></p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/novartis-commits-up-to-2-2b-toward-developing-arrowhead-sirna-therapy/\" rel=\"noopener noreferrer\" target=\"_blank\">Novartis Commits Up to $2.2B toward Developing Arrowhead siRNA Therapy</a></p><p>Alex Philippidis<em>, GEN Edge,</em> September 2, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/cancer/off-the-shelf-immunotherapy-demonstrates-multipronged-attack-against-cancer/\" rel=\"noopener noreferrer\" target=\"_blank\">Off-the-Shelf Immunotherapy Demonstrates Multipronged Attack Against Cancer</a></p><p><em>GEN,</em> August 29, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/human-macrophages-reprogrammed-by-electrical-stimulation-to-encourage-faster-healing/\" rel=\"noopener noreferrer\" target=\"_blank\">Human Macrophages “Reprogrammed” by Electrical Stimulation to Encourage Faster Healing</a></p><p><em>GEN,</em> September 2, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/gen-edge/stockwatch-analysts-see-10b-in-sales-for-lilly-oral-glp-1/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: Analysts See $10B+ in Sales for Lilly Oral GLP-1</a></p><p>Alex Philippidis,<em> GEN Edge,</em> September 1, 2025</p><p><br></p><p><a href=\"https://www.genengnews.com/category/multimedia/podcasts/touching-base/\" rel=\"noopener noreferrer\" target=\"_blank\">Touching Base Podcast</a></p><p>Hosted by Corinna Singleman, PhD</p><p><br></p><p><a href=\"https://www.insideprecisionmedicine.com/category/multimedia/podcasts/\" rel=\"noopener noreferrer\" target=\"_blank\">Behind the Breakthroughs</a></p><p>Hosted by Jonathan D. Grinstein, PhD</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}